Regeneron dans l'actualité
Médecine, science, santé, mondial
Tamtam a trouvé 20 articles récents sur Regeneron.
- Regeneron price target raised to $950 from $900 at JPMorgan
- Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial
- Regeneron sees nearly $0.18 per share earnings headwind in Q3
- Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
- Regeneron, Sanofi deepen antibody collaboration with expanded alliance
- Regeneron: The Easy Money Has Been Made (Rating Downgrade) (NASDAQ:REGN)
- Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
- EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
- #EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
- Regeneron Phase II trial confirms trevogrumab halves muscle loss
- Why Regeneron (REGN) Stock Is Trading Lower Today
- Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ)
- Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN)
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow (NASDAQ:REGN) 2026-10-01
- #EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy
- Sanofi and Regeneron expand global alliance
- Sanofi forges new $8bn pact with Regeneron
- Sanofi, Regeneron broaden alliance to find their next Dupixent
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Regeneron ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires